A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Jeffrey V. Lazarus et al.|Hepatology|2023Cited by 2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Marco Arrese et al.|Journal of Hepatology|2023Cited by 2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A. Neuschwander‐Tetri, Edward Doo, Rohit Loomba et al.|The Lancet|2014Cited by 2.2k
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisParambir S. Dulai, Rohit Loomba|Hepatology|2017Cited by 1.9k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Vlad Ratziu et al.|The Lancet|2019Cited by 1.2k